WhatsApp Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine By Digital AIM Web Support – February 8, 2021 Facebook BEIJING–(BUSINESS WIRE)–Feb 8, 2021– Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac, Sinovac’s COVID-19 vaccine in individuals aged 18 and above. Sinovac began rolling submission to the NMPA since September 2020 and the NMPA carried out rolling reviews when the submission was made. As of February 4, 2021, the Company made more than 40 submissions to the NMPA. After obtaining the preliminary efficacy results, Sinovac formally filed for application of a conditional marketing authorization on February 3, 2021. The approval is based on the results of the two-month data of phase III clinical trials. The final results are not yet available, and the efficacy and safety results shall be further confirmed. Mr. Yin Weidong, Chairman, President and CEO of Sinovac, said, “Being granted a conditional marketing authorization for CorornaVac is a significant milestone for Sinovac after commencing development at the beginning of 2020. We show our respect and appreciation to the volunteers for their contribution to this research and thank all experts, scientists and partners who participated in this international collaborative project. The COVID-19 pandemic continues around the world, and the fight is far from over. We look forward to providing safe and effective vaccines to as many individuals as possible to combat this epidemic by increasing the vaccination rate. It is our sincere hope that people’s lives and social and economic activities can return to normal as soon as possible, and that we can wear a smile without masks.” CoronaVac is being used under emergency use approval (EUA) in Indonesia, Brazil, Turkey and Chile. Sinovac is also actively seeking regulatory approval of CoronaVac in other countries and regions around the world in an effort to maximize global accessibility and affordability of the COVID-19 vaccine and to ensure global prevention and mitigate spread. About Sinovac Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide (“PPV”), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China. For more information please see the Company’s website at www.sinovac.com. Safe Harbor Statement This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan. This announcement contains forward-looking information about the Company’s efforts to develop a potential COVID-19 vaccine that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data (including the Phase III trial data); the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase III trials or in larger, more diverse populations upon commercialization; the risk that clinical trial data are subject to differing interpretations and assessments, and by regulatory authorities; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate; uncertainties regarding the ability to obtain recommendations public health authorities; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments. View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005305/en/ CONTACT: Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279-9871 or +86-10-5693-1897 Fax: +86-10-6296-6910 Email:[email protected] Inc. Bill Zima U.S.: 1-646-308-1707 Email:[email protected] KEYWORD: INDONESIA MIDDLE EAST UNITED ARAB EMIRATES BRAZIL TURKEY CHINA CHILE SOUTH AMERICA ASIA PACIFIC EUROPE INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Sinovac Biotech Ltd. Copyright Business Wire 2021. PUB: 02/08/2021 07:30 AM/DISC: 02/08/2021 07:31 AM http://www.businesswire.com/news/home/20210208005305/en TAGS Previous articleTumelo Skin Care Introduces So Sensitive! Body LotionNext articleMatterkind Expands Global Reach with Two Strategic Hires Digital AIM Web Support Twitter Pinterest WhatsApp Local NewsBusiness Pinterest Facebook Twitter
Related Articles February 6, 2018 1,894 Views Print This Post in Daily Dose, Featured, Headlines, Journal, Market Studies, News About Author: Scott Morgan Subscribe The Best Markets For Residential Property Investors 2 days ago At the end of Q4, home price values nationally were up year-over-year for the fifth consecutive month, according to the latest CoreLogic Home Price Index and HPI Forecast report.The report found that in December 2017, home prices in the United States were half a percent higher in December than in November and an average 6.6 percent higher than in December 2016. Higher growth rates occurred in the West, namely in California, Idaho, Nevada, Utah, and Washington.Moreover, CoreLogic reported, home price values are expected to be another 4.3 percent higher this coming December than they were at the end of 2017. CoreLogic expects monthly values this year to be about half a percent higher than their corresponding 2017 months were.Part of the reason home values are on such an upswing is the lingering shortage of houses available on the market, and part is a still-robust economy.“The number of homes for sale has remained very low,” said Dr. Frank Nothaft, Chief Economist for CoreLogic. “Job growth lowered the unemployment rate to 4.1 percent by year’s end, the lowest level in 17 years. Rising income and consumer confidence has increased the number of prospective homebuyers. The net result of rising demand and limited for-sale inventory is a continued appreciation in home prices.”Frank Martell, President and CEO of CoreLogic, credited the price growth to “aggressive monetary policy, the economic and jobs recovery, and a lack of housing stock.”This, Martell said, is making it tough for less affluent buyers to find homes to invest in.“As home prices and the cost of originating loans rise, affordability continues to erode, making it more challenging for both first-time buyers and moderate-income families to buy. At this point, we estimate that more than one-third of the 100 largest metropolitan areas are overvalued.”According to CoreLogic, 35 percent of the top 100 metropolitan areas had an overvalued housing market as of December. Almost half the top 50 markets were overvalued. Conversely, 28 percent of the top 100 metros and 14 percent of the top 50 metros were undervalued. Thirty-seven percent were where they should be. CoreLogic Home Price Index Home Values HOUSING HPI Forecast Q4 2018-02-06 Scott Morgan Demand Propels Home Prices Upward 2 days ago Data Provider Black Knight to Acquire Top of Mind 2 days ago Scott Morgan is a multi-award-winning journalist and editor based out of Texas. During his 11 years as a newspaper journalist, he wrote more than 4,000 published pieces. He’s been recognized for his work since 2001, and his creative writing continues to win acclaim from readers and fellow writers alike. He is also a creative writing teacher and the author of several books, from short fiction to written works about writing. Home / Daily Dose / Still No Peak in Sight for Home Values Previous: Bracing for a Sea of Change in Mortgage Servicing Next: For Tech in Mortgage, Constant Innovation is Key Tagged with: CoreLogic Home Price Index Home Values HOUSING HPI Forecast Q4 Data Provider Black Knight to Acquire Top of Mind 2 days ago Servicers Navigate the Post-Pandemic World 2 days ago Governmental Measures Target Expanded Access to Affordable Housing 2 days ago The Week Ahead: Nearing the Forbearance Exit 2 days ago Demand Propels Home Prices Upward 2 days ago The Best Markets For Residential Property Investors 2 days ago Servicers Navigate the Post-Pandemic World 2 days ago Still No Peak in Sight for Home Values Share Save Governmental Measures Target Expanded Access to Affordable Housing 2 days ago Sign up for DS News Daily
86 Diamond St, Holland Park.Mr Hay said Holland Park prices had surged over the last 12 months with people citing amenities, lifestyle and proximity to schools and transport as being the major factors for them searching in the area. 86 Diamond St, Holland Park. 86 Diamond St, Holland Park.Mr Hay said the five-bedroom, four-bathroom home also fetched a record sale price for the pocket known as the ‘Jewel Box’.The home features ducted multiple zoned air conditioning, internet cabling with multiple hard wired stations, garden irrigation system, mixed Australian hardwood flooring throughout, huge amounts of storage, ceiling fans in all bedrooms and living areas, and room for up to four cars and more than enough room to store a boat. 86 Diamond St, Holland Park.A building inspector has described this Brisbane property as the best renovation he has seen in the last 20 years.The property at 86 Diamond St, Holland Park recently sold for $1,213,500.Place — Coorparoo selling agent Scott Hay said the two-level home was bought by a local family.“It was a beautiful renovation, the owner had put a lot of care, money and effort into it and he painstakingly renovated it over the last two years,” Mr Hay said.“A building inspector described it as the best renovation he had seen in over 20 years”. FREE: Get the latest real estate news direct to your inbox here. More from newsMould, age, not enough to stop 17 bidders fighting for this homeless than 1 hour agoBuyers ‘crazy’ not to take govt freebies, says 28-yr-old investor6 hours agoThe pool area at 86 Diamond St, Holland Park.
Share this:FacebookRedditTwitterPrintPinterestEmailWhatsAppSkypeLinkedInTumblrPocketTelegram The Nigeria U-20 squad yesterday flew into Calabar, capital of Cross River State as the football –loving State returns to the front burner of international football action.Coach Emmanuel Amuneke led a group of 25 players and three officials into Canaan City, as the Flying Eagles intensify preparations for weekend’s 2017 Africa U-20 Cup of Nations qualifying match against the Young Swallows of Burundi.Calabar is hosting the return leg match this Saturday, which should be a soft session for the African champions, who pipped the Young Swallows 1-0 in Bujumbura two weeks ago.Meanwhile, Chile 2015 FIFA U-17 World Cup bronze ball winner Samuel Chukwueze has continued in fine form in friendly matches ahead of the clash, causing serious havoc to opposition defence –lines.Just two days after his brace helped the Flying Eagles demolish Nigeria National League side, Shekarau Babes FC in a friendly match played on the artificial pitch of the FIFA Goal Project in Abuja, the winger was again at his imperious best netting twice in the second half as the Emmanuel Amuneke tutored side saw off Amakson Football Academy 3-0 in another friendly match at the weekend at the same venue.The galloping winger was at his usual slippery best all through the entertaining affair and received huge applause from the crowd, among them players of the National U-17 team currently in Abuja for a screening exercise supervised by team Coach Manu Garba.The UJ Esuene Stadium, which has played host to several Super Eagles and Golden Eaglets’ international matches over the past few years, will host this weekend’s clash between the Flying Eagles and the Young Swallows. The winner on aggregate will reach the final round of the qualification series for the 2017 Africa U-20 Cup of Nations, where Sudan will be the opposition.